中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 8
Aug.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(8): 1932-1938

Effect of immune checkpoint molecules on the function of natural killer cells in patients with chronic hepatitis B virus infection

DOI: 10.3969/j.issn.1001-5256.2023.08.025
  • 1.

    The First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou 730000, China

  • 2.

    Department of Gastroenterology, The 940 Hospital of Joint Logistic Support Force of PLA, Lanzhou 730050, China

  • 3.

    Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou 730030, China

Research funding:

Gansu Clinical Medical Research Center for Non-infectious Liver Diseases (21JR7RA017);

Project of Excellent Youth Team Training for the Central Universities (31920220065);

The Top Project of The 940 Hospital (2021yxky02)

More Information
  • Corresponding author: ZHENG Xiaofeng, zhengxf19892013@126.com (ORCID: 0009-0002-9660-1224); ZHANG Jiucong, zhangjiucong@163.com (ORCID: 0000-0003-4006-3033)
  • Received Date: 2022-11-01
  • Accepted Date: 2022-12-18
  • Published Date: 2023-08-20
    Abstract
  • At present, the mechanism of chronic hepatitis B virus (HBV) infection has not been fully clarified, and HBV can cause immune cell dysfunction, immune imbalance and functional defects in the host, which might be one of the mechanisms of chronic HBV infection. In chronic HBV infection, the functions of natural killer (NK) cells are depleted, which may be associated with the upregulated expression of immune checkpoint molecules on the surface of NK cells, and blocking immune checkpoint molecules can restore the function of NK cells. This article systematically reviews the etiology of HBV, the mechanism of chronic HBV infection, and the effect of common immune checkpoint molecules on functions of NK cells in chronic hepatitis B, so as to provide new ideas for the treatment of chronic HBV infection.

     

    • FullText(HTML)
  • loading
    • References(55)
  • [1]
    WHO. Hepatitis B[EB/OL]. (2022-06-24)[2022-10-20]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
    [2]
    ZHU M, WANG H, LOU T, et al. Current treatment of chronic hepatitis B: Clinical aspects and future directions[J]. Front Microbiol, 2022, 13: 975584. DOI: 10.3389/fmicb.2022.975584.
    [3]
    MADHUSOODANAN J. Research round-up: hepatitis B[J]. Nature, 2022, 603(7903): S66-S67. DOI: 10.1038/d41586-022-00822-z.
    [4]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [5]
    RAMJI A, DOUCETTE K, COOPER C, et al. Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue[J]. World J Gastroenterol, 2022, 28(31): 4390-4398. DOI: 10.3748/wjg.v28.i31.4390.
    [6]
    BUSCA A, KUMAR A. Innate immune responses in hepatitis B virus (HBV) infection[J]. Virol J, 2014, 11: 22. DOI: 10.1186/1743-422X-11-22.
    [7]
    MAEPA MB, ELY A, KRAMVIS A, et al. Hepatitis B virus research in South Africa[J]. Viruses, 2022, 14(9): 1939. DOI: 10.3390/v14091939.
    [8]
    SKRLEC I, TALAPKO J. Hepatitis B and circadian rhythm of the liver[J]. World J Gastroenterol, 2022, 28(27): 3282-3296. DOI: 10.3748/wjg.v28.i27.3282.
    [9]
    TSOUNIS EP, TOURKOCHRISTOU E, MOUZAKI A, et al. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure[J]. World J Gastroenterol, 2021, 27(21): 2727-2757. DOI: 10.3748/wjg.v27.i21.2727.
    [10]
    BONINO F, COLOMBATTO P, BRUNETTO M R. HBeAg-negative/anti-HBe-positive chronic hepatitis B: a 40-year-old history[J]. Viruses, 2022, 14(8): 1691. DOI: 10.3390/v14081691.
    [11]
    SEEGER C, MASON WS. Molecular biology of hepatitis B virus infection[J]. Virology, 2015, 479-480: 672-686. DOI: 10.1016/j.virol.2015.02.031.
    [12]
    JIN X, YAN ZH, LU L, et al. Peripheral immune cells exhaustion and functional impairment in patients with chronic hepatitis B[J]. Front Med (Lausanne), 2021, 8: 759292. DOI: 10.3389/fmed.2021.759292.
    [13]
    SAJID M, LIU L, SUN C. The dynamic role of NK cells in liver cancers: role in HCC and HBV associated HCC and its therapeutic implications[J]. Front Immunol, 2022, 13: 887186. DOI: 10.3389/fimmu.2022.887186.
    [14]
    LI HJ, YANG N, MU X, et al. Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Hepatol Int, 2022, 16(6): 1398-1411. DOI: 10.1007/s12072-022-10386-9.
    [15]
    LI Y, WANG JJ, GAO S, et al. Decreased peripheral natural killer cells activity in the immune activated stage of chronic hepatitis B[J]. PLoS One, 2014, 9(2): e86927. DOI: 10.1371/journal.pone.0086927.
    [16]
    LI X, ZHOU L, GU L, et al. Veritable antiviral capacity of natural killer cells in chronic HBV infection: an argument for an earlier anti-virus treatment[J]. J Transl Med, 2017, 15(1): 220. DOI: 10.1186/s12967-017-1318-1.
    [17]
    MONDELLI MU, VARCHETTA S, OLIVIERO B. Natural killer cells in viral hepatitis: facts and controversies[J]. Eur J Clin Invest, 2010, 40(9): 851-863. DOI: 10.1111/j.1365-2362.2010.02332.x.
    [18]
    SUN C, SUN HY, XIAO WH, et al. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy[J]. Acta Pharmacol Sin, 2015, 36(10): 1191-1199. DOI: 10.1038/aps.2015.41.
    [19]
    CHEN Y, TIAN Z. HBV-induced immune imbalance in the development of HCC[J]. Front Immunol, 2019, 10: 2048. DOI: 10.3389/fimmu.2019.02048.
    [20]
    YU L, LIU X, WANG X, et al. TIGIT+ TIM-3+ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Oncoimmunology, 2021, 10(1): 1942673. DOI: 10.1080/2162402X.2021.1942673.
    [21]
    WANG X, XIONG H, NING Z. Implications of NKG2A in immunity and immune-mediated diseases[J]. Front Immunol, 2022, 13: 960852. DOI: 10.3389/fimmu.2022.960852.
    [22]
    LI F, WEI H, WEI H, et al. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice[J]. Gastroenterology, 2013, 144(2): 392-401. DOI: 10.1053/j.gastro.2012.10.039.
    [23]
    MA Q, DONG X, LIU S, et al. Hepatitis B e antigen induces NKG2A+ natural killer cell dysfunction via regulatory T cell-derived interleukin 10 in chronic hepatitis B virus Infection[J]. Front Cell Dev Biol, 2020, 8: 421. DOI: 10.3389/fcell.2020.00421.
    [24]
    PERUZZI G, MASILAMANI M, BORREGO F, et al. Endocytosis as a mechanism of regulating natural killer cell function: unique endocytic and trafficking pathway for CD94/NKG2A[J]. Immunol Res, 2009, 43(1-3): 210-222. DOI: 10.1007/s12026-008-8072-7.
    [25]
    LI PW, SHEN YQ. Effect of immune-checkpoint molecules on T-cell function in chronic infection with the HBV[J]. J Virol, 2021, 37(2): 465-470. DOI: 10.13242/j.cnki.bingduxuebao.003914.

    李鹏尉, 沈宇清. 免疫检查点分子在慢性HBV感染中对T细胞功能影响的研究进展[J]. 病毒学报, 2021, 37(2): 465-470. DOI: 10.13242/j.cnki.bingduxuebao.003914.
    [26]
    WANG Y, ZHANG H, LIU C, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts[J]. J Hematol Oncol, 2022, 15(1): 111. DOI: 10.1186/s13045-022-01325-0.
    [27]
    LI H, ZHAI N, WANG Z, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection[J]. Gut, 2018, 67(11): 2035-2044. DOI: 10.1136/gutjnl-2017-314098.
    [28]
    LI F. Correlation between the expression of PD-1/PD-L1 on NK cells and HBV infection[D]. Hengyang: University of South China, 2020.

    李芬. NK细胞上PD-1/PD-L1表达与HBV感染相关性研究[D]. 衡阳: 南华大学, 2020.
    [29]
    QUATRINI L, MARIOTTI F R, MUNARI E, et al. The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy[J]. Cancers (Basel), 2020, 12(11): 3285. DOI: 10.3390/cancers12113285.
    [30]
    BAI R, CUI J. Burgeoning exploration of the role of natural killer cells in Anti-PD-1/PD-L1 therapy[J]. Front Immunol, 2022, 13: 886931. DOI: 10.3389/fimmu.2022.886931.
    [31]
    WOLF Y, ANDERSON AC, KUCHROO VK. TIM3 comes of age as an inhibitory receptor[J]. Nat Rev Immunol, 2020, 20(3): 173-185. DOI: 10.1038/s41577-019-0224-6.
    [32]
    CAI X, ZHAN H, YE Y, et al. Current progress and future perspectives of immune checkpoint in cancer and infectious diseases[J]. Front Genet, 2021, 12: 785153. DOI: 10.3389/fgene.2021.785153.
    [33]
    LIU Y, GAO LF, LIANG XH, et al. Role of Tim-3 in hepatitis B virus infection: An overview[J]. World J Gastroenterol, 2016, 22(7): 2294-2303. DOI: 10.3748/wjg.v22.i7.2294.
    [34]
    JU Y, HOU N, MENG J, et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B[J]. J Hepatol, 2010, 52(3): 322-329. DOI: 10.1016/j.jhep.2009.12.005.
    [35]
    YANG X, LI M, QIN X, et al. Photophosphatidylserine guides natural killer cell photoimmunotherapy via tim-3[J]. J Am Chem Soc, 2022, 144(9): 3863-3874. DOI: 10.1021/jacs.1c11498.
    [36]
    TAN S, XU Y, WANG Z, et al. Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling[J]. Cancer Res, 2020, 80(5): 1130-1142. DOI: 10.1158/0008-5472.CAN-19-2332.
    [37]
    JIAO J, JIAO D, YANG F, et al. Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma[J]. Aging (Albany NY), 2022, 14(4): 1879-1890. DOI: 10.18632/aging.203909.
    [38]
    LI WQ, YU X, HOU ZH, et al. HBV impairs the function of NK cells by upregulating Galectin-9 expression on hepatocytes[J]. Current Immunology, 2014, 34(6): 471-477. https://www.cnki.com.cn/Article/CJFDTOTAL-SHMY201406006.htm

    李卫群, 于馨, 侯召华, 等. HBV通过上调肝细胞表面Galectin-9的表达抑制NK细胞的功能[J]. 现代免疫学, 2014, 34(6): 471-477. https://www.cnki.com.cn/Article/CJFDTOTAL-SHMY201406006.htm
    [39]
    LI HR, ZHANG FQ, ZHANG ZC, et al. Research progress on mechanism of immunosuppressive receptor TIGIT in pathogen infection[J]. Chin J Immunol, 2022, 38(5): 632-637. DOI: 10.3969/j.issn.1000-484X.2022.05.022.

    李浩然, 张富强, 张振超, 等. 免疫抑制性受体TIGIT在病原体感染中的作用机制研究进展[J]. 中国免疫学杂志, 2022, 38(5): 632-637. DOI: 10.3969/j.issn.1000-484X.2022.05.022.
    [40]
    JEONG BS, NAM H, LEE J, et al. Structural and functional characterization of a monoclonal antibody blocking TIGIT[J]. MAbs, 2022, 14(1): 2013750. DOI: 10.1080/19420862.2021.2013750.
    [41]
    YAO F, YIN X. Regulatory effect of immune checkpoint TIGIT/CD155 on the immune microenvironment of primary liver cancer and its application prospects[J]. J Clin Hepatol, 2022, 38(11): 2632-2635. DOI: 10.3969/j.issn.1001-5256.2022.11.039.

    姚帆, 殷欣. 免疫检查点TIGIT/CD155对原发性肝癌免疫微环境的调控作用及应用展望[J]. 临床肝胆病杂志, 2022, 38(11): 2632-2635. DOI: 10.3969/j.issn.1001-5256.2022.11.039.
    [42]
    YEO J, KO M, LEE DH, et al. TIGIT/CD226 axis regulates anti-tumor immunity[J]. Pharmaceuticals (Basel), 2021, 14(3): 200. DOI: 10.3390/ph14030200.
    [43]
    MOLFETTA R, ZITTI B, LECCE M, et al. CD155: a multi-functional molecule in tumor progression[J]. Int J Mol Sci, 2020, 21(3): 922. DOI: 10.3390/ijms21030922.
    [44]
    KUZEVANOVA A, APANOVICH N, MANSORUNOV D, et al. The features of checkpoint receptor-ligand interaction in cancer and the therapeutic effectiveness of their inhibition[J]. Biomedicines, 2022, 10(9): 2081. DOI: 10.3390/biomedicines10092081.
    [45]
    ANNESE T, TAMMA R, RIBATTI D. Update in TIGIT immune-checkpoint role in cancer[J]. Front Oncol, 2022, 12: 871085. DOI: 10.3389/fonc.2022.871085.
    [46]
    LU Y, SUN R, TIAN ZG, et al. Study on role of TIGIT in HBV immunotherapy[J]. Chin J Immunol, 2022, 38(2): 129-134. DOI: 10.3969/j.issn.1000-484X.2022.02.001.

    卢杨, 孙汭, 田志刚, 等. TIGIT分子在HBV免疫治疗中的作用探究[J]. 中国免疫学杂志, 2022, 38(2): 129-134. DOI: 10.3969/j.issn.1000-484X.2022.02.001.
    [47]
    KHAN M, AROOJ S, WANG H. NK cell-based immune checkpoint inhibition[J]. Front Immunol, 2020, 11: 167. DOI: 10.3389/fimmu.2020.00167.
    [48]
    LI YL, ZHANG QF, YIN WW, et al. Reduced frequency of natural killer cell on siglec-7(+) is associated with progression of hepatitis B virus-related cirrhosis[J]. Chin J Hepatol, 2018, 26(6): 420-425. DOI: 10.3760/cma.j.issn.1007-3418.2018.06.006.

    李彦霖, 张琼方, 殷文伟, 等. Siglec-7+自然杀伤细胞频数下降与乙型肝炎病毒相关肝硬化疾病进展相关[J]. 中华肝脏病杂志, 2018, 26(6): 420-425. DOI: 10.3760/cma.j.issn.1007-3418.2018.06.006.
    [49]
    ZHAO D, JIANG X, XU Y, et al. Decreased siglec-9 expression on natural killer cell subset associated with persistent HBV replication[J]. Front Immunol, 2018, 9: 1124. DOI: 10.3389/fimmu.2018.01124.
    [50]
    ALFARRA H, WEIR J, GRIEVE S, et al. Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy[J]. Front Immunol, 2020, 11: 575609. DOI: 10.3389/fimmu.2020.575609.
    [51]
    NARAYANAN S, AHL PJ, BIJIN VA, et al. LAG3 is a central regulator of NK cell cytokine production[J]. bioRxiv, 2020. DOI: 10.1101/2020.01.31.928200.[Olineaheadofprint]
    [52]
    WANG J, HOU H, MAO L, et al. TIGIT signaling pathway regulates natural killer cell function in chronic hepatitis B virus infection[J]. Front Med (Lausanne), 2021, 8: 816474. DOI: 10.3389/fmed.2021.816474.
    [53]
    REVILL PA, CHISARI FV, BLOCK JM, et al. A global scientific strategy to cure hepatitis B[J]. Lancet Gastroenterol Hepatol, 2019, 4(7): 545-558. DOI: 10.1016/S2468-1253(19)30119-0.
    [54]
    INC AP. Ascletis announces results of the phase Ⅱa trial of ASC22 (Envafolimab) in patients with chronic hepatitis B to be presented in oral parallel session at the liver meetingⓇ 2021 by American Association for the Study of Liver Diseases[EB/OL]. (2021-10-11)[2022-10-20]. https://www.prnewswire.com/news-releases/ascletis-announces-results-of-the-phase-iia-trial-of-asc22-envafolimab-in-patients-with-chronic-hepatitis-b-to-be-presented-in-oral-parallel-session-at-the-liver-meeting-2021-by-american-association-for-the-study-of-liver-disea-301396930.html.
    [55]
    MARKHAM A. Envafolimab: first approval[J]. Drugs, 2022, 82(2): 235-240. DOI: 10.1007/s40265-022-01671-w.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (456) PDF downloads(50) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return